Phase III Study in China Shows 48-Week Data on Telitacicept for Generalized Myasthenia Gravis

YANTAI, China — Researchers have presented findings from a Phase III clinical study conducted in China on telitacicept, a dual-target fusion protein drug developed for the treatment of generalized myasthenia gravis. The 48-week open-label extension (OLE) data from the study has been selected for an oral presentation at the 2025 Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM). Telitacicept, also known as RC18 and marketed under the brand name 泰爱®, is designed to target BLyS and APRIL, two proteins involved in autoimmune diseases.

The clinical trial evaluated the safety and efficacy of telitacicept over an extended period. Generalized myasthenia gravis is a chronic autoimmune disorder that affects neuromuscular function, leading to muscle weakness. The selection of this data for presentation at AANEM highlights its potential significance in advancing treatment options for this condition. RemeGen, the company behind telitacicept, has independently developed this innovative drug as part of its efforts to address unmet medical needs in autoimmune diseases. Further details regarding the study outcomes are expected to be shared during the AANEM meeting later this year.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 18, 2025

Related posts:

Makary Navigates FDA Reshaping Amidst Impending Budget Cuts FDA Withdraws Defense of LDT Rule Amid Potential Increased Scrutiny on RUO Products State Laws Expand Pharmacists’ Roles to Include Prescribing and Chronic Care Management Study Finds Well-Being and Ill-Being as Distinct Constructs in Older Adults’ Mental Health

Author

Mark Chiang